Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease.

Becker, Heike E F; Demers, Karlijn; Derijks, Luc J J; Jonkers, Daisy M A E; Penders, John

Becker, Heike E F; Demers, Karlijn; Derijks, Luc J J; Jonkers, Daisy M A E; Penders, John.

Afiliación

Becker HEF; Division Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, Netherlands.
Demers K; Department of Medical Microbiology, Infectious Diseases and Infection Prevention, NUTRIM School of Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, Netherlands.
Derijks LJJ; Division Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, Netherlands.
Jonkers DMAE; Department of Clinical Pharmacy and Pharmacology, Máxima Medical Center, Veldhoven, Netherlands.
Penders J; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, Netherlands.

Front Microbiol ; 14: 1107976, 2023.

Article en En | MEDLINE | ID: mdl-36910207

Palabras clave

Crohn's disease; drug metabolism; drug treatment; inflammatory bowel disease; microbiome; pharmacomicrobiomics; ulcerative colitis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Microbiol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google